SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Investors are actively debating the legitimacy of a tokenized crypto asset claiming to offer pre-IPO exposure to SpaceX, with many community members labeling it a scam and warning against potential pump-and-dump schemes. While participants look for ways to gain exposure to the rumored SpaceX IPO through related stocks and space-sector ETFs, experts emphasize that official equity is not currently available to the public.

Fartcoin is a meme-driven cryptocurrency where users can submit their best fart jokes or memes to earn initial tokens. Each transaction triggers a hilarious 'Gas Fee' effect, complete with a digital fart sound for maximum comedic impact.

Fartcoin

Fartcoin is seeing intense community engagement as investors debate its potential for a major breakout, with the conversation dominated by meme-centric hype, speculative price predictions, and comparisons to other viral meme tokens. The discussion remains polarized between bullish sentiment fueled by historical price action and skepticism regarding the long-term utility of the project.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

Grayscale Bitcoin Trust (GBTC) is trending as the community debates Bitcoin's long-term trajectory and institutional adoption, with sentiment split between long-term bullish holders betting on cyclical gains and short-term traders warning of potential volatility as BTC faces resistance levels. Investors are actively discussing the impact of broader economic indicators, regulatory shifts, and leverage trends on the asset's momentum.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp. (EMAT) is capturing intense retail attention as investors bet on its potential to challenge the domestic supply chain for rare earth magnets. The community is focused on the stock's low-float, volatile trading patterns, with active discussions debating whether its tech-integrated mining approach is a legitimate long-term play or a short-term pump and dump.

Investment Managers Series Trust II - Tradr 2X Long AAOI Daily ETF

The Tradr 2X Long AAOI Daily ETF

AAOX is generating significant community conversation as a leveraged vehicle for traders looking to amplify their exposure to the volatile price action in Applied Optoelectronics. Investors are actively debating the merits of this high-risk tool, focusing on its use for short-term momentum plays and potential short squeezes within the broader optical networking and AI-related tech sector.

XYO is the original and one of the largest Decentralized Physical Infrastructure Networks (DePIN), boasting over 10 million nodes and consistently leading DePIN in both scale and revenue generation. Launching its Mainnet ahead of any other DePIN, XYO specializes in collecting and validating real-world data, bridging it seamlessly to Web3 and Web2 companies across AI, geolocation, and other critical data sectors. At the core of XYO are Proof of Location and Proof of Origin technologies, enabling accurate validation of real-world data for innovative use cases such as Real-World Asset (RWA) tracking, DePIN applications, real-world gaming, and treasure hunts. Recently, XYO expanded its ecosystem by launching the XYO Layer One blockchain, purpose-built to support the intensive data demands of DePIN, RWA, AI, and similar data-driven industries. XYO employs a unique dual-token model: XYO Token: An externally traded token supporting the DePIN ecosystem, rewards, staking, and governance, enhancing overall ecosystem value and scarcity.   XL1 Token: Internal to the XYO Layer One blockchain, facilitating transactions, gas fees, and other blockchain-specific use cases. The dual-token economics are strategically designed to increase scarcity and promote sustainable growth. The XYO token is available on major exchanges, including Coinbase. The XL1 token will launch publicly later in 2025. To accelerate network adoption and growth, XYO created the popular COIN app. Beyond the XYO Foundation, the team founded the U.S.-based, for-profit entity XY Labs Inc., notable as the first U.S. crypto company qualified by the SEC for a Regulation A offering, permitting share sales to both accredited and non-accredited investors. XY Labs further stands out as one of the pioneering U.S. companies to tokenize and publicly list its shares. These tokenized shares trade as $XYLB on the tZERO ATS, positioning XY Labs prominently in the growing wave of Real-World Asset (RWA) tokenization.

XYO Network

XYO Network is trending as investors debate the potential of its DePin infrastructure and long-term utility against persistent frustration over its history of pump-and-dump price action. Community sentiment remains deeply polarized, with many users expressing skepticism over past broken promises and project leadership while others aggressively accumulate, citing bullish signals and upcoming ecosystem developments.

Sprinklr, Inc. engages in the provision of enterprise cloud software products. It enables organizations to do marketing, advertising, research, care, sales, and engagement across modern channels including social, messaging, chat, and text through its unified customer experience management software platform. The company was founded by Ragy Thomas on September 24, 2009 and is headquartered in New York, NY.

Sprinklr Inc - Ordinary Shares Class A

Sprinklr Inc

Sprinklr is trending as investors weigh significant insider selling and legal concerns against bullish sentiment driven by institutional accumulation and the company's AI-native platform. The community is actively debating whether the stock's recent price pressure creates a long-term value opportunity or reflects ongoing governance and growth challenges.

Canadian Natural Resources Ltd. is an oil and natural gas production company, which engages in the exploration, development, marketing, and production of crude oil and natural gas. It operates through the following segments: Oil Sands Mining & Upgrading, Midstream & Refining, and Exploration & Production. The Oil Sands Mining & Upgrading segment produces synthetic crude oil through bitumen mining and upgrading operations. The Midstream & Refining segment focuses on maintaining pipeline operations and investment. The Exploration & Production segment consists of operations in North America, largely in Western Canada, the United Kingdom portion of the North Sea, and Côte d’Ivoire and South Africa in Africa. The company was founded on November 7, 1973 and is headquartered in Calgary, Canada.

Canadian Natural Resources Ltd.

Canadian Natural Resources is trending as investors highlight its resilient oil sands production, consistent dividend growth streak, and strong cash flow generation despite broader market volatility. The community remains focused on the company's status as a top-tier energy producer, emphasizing its long-term value and operational efficiency in an evolving energy landscape.

Vanguard World Fund - Vanguard Energy ETF

Vanguard Energy ETF

Vanguard Energy ETF (VDE) is trending as investors react to high energy prices, geopolitical tensions in the Middle East, and ongoing concerns regarding global supply chain disruptions. Community members are actively debating the long-term growth potential of energy assets amidst persistent inflationary pressures and shifting supply-demand dynamics.

APA Corp. explores for oil and natural gas through its subsidiaries. It produces oil and gas with operations in the United States, Egypt and the United Kingdom, and exploration activities offshore in Suriname. The company was founded in 1954 and is headquartered in Houston, TX.

APA Corporation

APA Corporation is trending as investors weigh recent workforce reductions alongside ongoing speculation regarding potential M&A activity and the company's long-term exploration projects in Suriname. Community discussions are heavily focused on the stock's perceived undervaluation relative to its assets and the broader impact of geopolitical volatility on energy sector sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

US-Iran Ceasefire Hopes Fade: ETF Strategies to Play 

U.S.-Iran tensions rise as Hormuz risks grow. Markets turn volatile -- dividend, low-beta, and defensive ETFs may help cushion portfolios.

Goldman Sachs Lifts UnitedHealth Target Price: Healthcare ETFs to Watch

Goldman lifts UnitedHealth's target price, spotlighting ETFs like IHF as diversified ways to tap its growth while cushioning Medicaid-driven risks.

Should You Invest in the Vanguard Health Care Index Fund ETF Shares (VHT)?

<ul class="summary-bullets"><li>Last year, Financial Times reported that big pharma company Merck had attempted to acquire MoonLake for over $3 billion though the approach was rejected.</li><li>MoonLake over the weekend announced that two of its late-stage trials in Hidradenitis suppurativa (HS) showed that clinical responses continue to improve to Week 40.</li><li>Currently, FDA approved medicines for HS include Novartis’s Cosentyx and AbbVie’s Humira.</li></ul>Shares of MoonLake Immunotherapeutics (MLTX) garnered retail interest on Tuesday on the heels of the company announcing long-term results from its late-stage clinical trials in moderate-to-severe hidradenitis suppurativa.On Stocktwits, retail sentiment around MLTX stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user highlighted optimism for a buyout for MoonLake, highlighting other recent mergers and acquisitions in the pharma industry, such as Biogen’s buyout of Apellis.<stembedurl>https://www.stocktwits.com/Bigpapa46/message/649036046</stembedurl>Last year, Financial Times reported that big pharma company Merck had attempted to acquire MoonLake for over $3 billion though the approach was rejected.Another user said that they are eyeing the stock breaching $19 levels.<stembedurl>https://www.stocktwits.com/Mr_GA/message/649091749</stembedurl>Yet another lauded the stock as the “Best buy in clinical biopharma,” while adding that it guarantees a “massive payday.”<stembedurl>https://www.stocktwits.com/Creisi/message/649090006</stembedurl><h2 class="st-heading-2">MoonLake’s Recent Data Reveal</h2>MoonLake over the weekend announced that two of its late-stage trials in Hidradenitis suppurativa (HS) showed that clinical responses continue to improve to Week 40, with 62% of patients treated with sonelokimab (SLK) achieving 75% reduction in abscess and inflammatory nodule count. Hidradenitis suppurativa (HS) is a chronic, noncontagious inflammatory skin condition causing painful, recurring lumps and abscesses, often leading to scarring and tunnels under the skin.According to MoonLake, the data sets a new standard in long-term lesion control of HS as approved drugs only reported similar reduction in symptoms for about 40% and 60% of subjects, respectively, at the 1-year mark of their respective pivotal trials.Currently, FDA approved medicines for HS include Novartis’s Cosentyx and AbbVie’s Humira.According to data from Koyfin, 12 of the 16 analysts covering MLTX rate it ‘Buy’ or higher while two rate ‘Hold’ and the remaining two rate it ‘Sell.’ The 12-month average price target on the stock is at $26.71, representing a potential upside of about 41%.<a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> slumped 52% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-rallies-in-anticipation-of-upbeat-q1-delivery-numbers-after-america-expansion-efforts/cZE5cWMRIVp">Nio Stock Rallies In Anticipation Of Upbeat Q1 Delivery Numbers After America Expansion Efforts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data

A Stocktwits user highlighted optimism for a buyout for MoonLake, highlighting other recent mergers and acquisitions in the pharma industry, such as Biogen’s buyout of Apellis.

Equity

A Stocktwits user highlighted optimism for a buyout for MoonLake, highlighting other recent mergers and acquisitions in the pharma industry, such as Biogen’s buyout of Apellis.


Healthcare ETFs in Spotlight Amid Eli Lily's $2.8B AI Drug Move

Eli Lilly's $2.75B AI drug deal with Insilico spotlights healthcare ETFs as investors seek diversified exposure to the fast-growing AI-driven pharma space. 

Stagflation Scare? ETFs May Help Protect Your Portfolio

Are stagflation risks returning as oil-driven inflation rises amid Middle East tensions? Here's how ETFs can help defend portfolios.

<ul class="summary-bullets"><li>The company stated that its trial demonstrated that 55% of the patients showed a 30% or greater reduction in lesion size compared to the control group.</li><li>Ocugen also noted a 27% slower rate of damage to important eye cells, which is linked to better vision.</li><li>The company also added that a subgroup analysis showed a 33% reduction in lesion growth compared to the control group in the medium-dose OCU410, while similar reductions were observed in the high-dose group.</li></ul>Ocugen Inc. (OCGN) shares tanked more than 13% in Tuesday’s opening trade after the company announced an update in its gene therapy trial for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).Ocugen said 12-month Phase 2 trial data showed its drug OCU410 significantly reduced lesion growth at the dose planned for Phase 3.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/OCGN">Ocugen</a> trended in the ‘neutral’ territory, with message volumes at ‘high’ levels.<h2 class="st-heading-2">What Did Ocugen Announce?</h2>Ocugen stated that its trial demonstrated that 55% of the patients in the study showed a reduction of 30% or more in the lesion size when compared to the control group. The company also noted that there was a 27% slower rate of damage to important eye cells, which is linked to better vision.Ocugen also added that a subgroup analysis showed 33% reduction in lesion growth compared to the control group in medium dose OCU410, while similar reductions were observed in the high dose group.“We have confirmed robust treatment effect from a well-controlled Phase 2 trial of a genetic medicine for GA. Now we can move on to Phase 3 with a high degree of confidence,” said Ocugen CEO Shankar Musunuri.The company stated that the global prevalence of dAMD is 266 million, while GA affects approximately up to three million people in the U.S. and Europe. The company says this number is expected to increase significantly as populations age.GA is an advanced stage of dAMD marked by progressive damage to the macula, resulting in permanent loss of central vision.Ocugen said that there were no OCU410-related serious adverse events observed in the Phase 2 trial. It also said that there were no cases of endophthalmitis, retinal detachment, vasculitis, choroidal neovascularization, or ischemic optic neuropathy reported to date.<h2 class="st-heading-2">What Does Ocugen Do?</h2>Ocugen is a Malvern, Pennsylvania-based biotechnology company that is developing novel gene therapies to address major blindness diseases.OCU410 is an investigational gene therapy injected under the retina that delivers RORA, a protein that controls key pathways involved in protecting and maintaining the retina.<a href="https://stocktwits.com/symbol/OCGN">OCGN stock</a> is up 36% year-to-date and 187% over the past 12 months. The S&amp;P Kensho New Economies Composite ETF (KOMP) is up 21% over the past 12 months, while the Vanguard Health Care Index Fund ETF Shares (VHT) is down 1%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-li-stock-rising-today/cZ3nKYIRIKv">China’s Tesla Rival Li Auto Announces $1 Share Repurchase Program — LI Stock Gains</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of US biotechnology company Ocugen Inc is displayed on a smartphone

OCGN Stock Tanks After Gene Therapy Trial Update — What Did Ocugen Announce?

Ocugen said 12-month Phase 2 trial data showed its drug OCU410 significantly reduced lesion growth at the dose planned for Phase 3.

Middle East Turmoil and U.S. Debt Surge: ETFs in Focus

With U.S. budget deficits and already elevated debt, the ongoing Middle East war could worsen the fiscal outlook, making defensive ETF strategies worth considering for stability.

ETFs to Play as Oil Surges Past $110 on Middle East Conflict 

Oil above $110 amid Middle East conflict is rattling markets. Here are ETF strategies -- from dividends and defensives to commodities -- that could help navigate the volatility.

<ul class="summary-bullets"><li>CorMedix’s Q4 revenue included $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio.</li><li>Total operating expenses for Q4 rose to $48.2 million, up 181% year-on-year.</li><li>CorMedix ended 2025 with $148.5 million in cash, cash equivalents, and short-term investments.</li></ul>CorMedix Inc. (CRMD) stock gained attention on Thursday, after the company announced its fourth-quarter (Q4) and full-year financial results for 2025, reporting a 312% year-on-year (YoY) jump in revenue.&nbsp;The company reported Q4 revenue of $128.6 million and an earnings per share (EPS) of $0.16. Though CorMedix’s revenue surpassed analysts’ consensus estimate of $127 million, EPS came in way below the estimated $0.82, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">What Are Stocktwits Users Saying?&nbsp;</h2><a href="https://stocktwits.com/symbol/CRMD">CorMedix stock</a> traded over 11% lower on Thursday morning. However, on Stocktwits, retail sentiment around the stock flipped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘high’ from ‘low’ in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_05_092009_png_aaa43e3104.webp" alt="CRMD’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Mar. 5, 2026 | Source: Stocktwits" width="930" height="102"><figcaption>CRMD’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Mar. 5, 2026 | Source: Stocktwits</figcaption></figure>A Stocktwits user said they are going long on the stock and hope to keep it until it climbs back to double digits.<stembedurl>https://stocktwits.com/JamesTiberius/message/646666139</stembedurl><h2 class="st-heading-2">Revenue Growth Driven by DefenCath and Melinta Acquisition</h2>CorMedix’s Q4 revenue included $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio. The Melinta revenue reflects the company’s first full quarter of contribution since its August 2025 acquisition.&nbsp;Total operating expenses for Q4 rose to $48.2 million, up 181% YoY. The expense increase primarily stems from the Melinta acquisition and includes $4.1 million in one-time costs, such as severance and integration expenses.&nbsp;<blockquote>“I am proud of the company’s progress over the past year as we have accelerated the expansion of patient access for DefenCath, completed our acquisition and integration of Melinta, and saw progress in our two ongoing Phase 3 clinical programs for Rezzayo prophylaxis and DefenCath in TPN.”-Joe Todisco, Chairman and CEO, CorMedix&nbsp;</blockquote>CorMedix ended 2025 with $148.5 million in cash, cash equivalents, and short-term investments, excluding restricted cash.CRMD stock has declined by over 37% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/help-stock-tanks-despite-strong-phase-2-results-for-anxiety-treatment-retail-buys-the-dip-ignoring-market-s-pessimism/cZdQHEpRI3O">HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Did CRMD Stock Tumble Over 11% Today?

The company reported mixed Q4 results with a revenue of $128.6 million and earnings per share of $0.16. 

VHT
Vanguard Health Care ETF

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest VHT News

VHTVanguard Health Care ETF